Company intelligence / Profile preview

Sarkana Pharma, Inc.

Wilmington, Delaware, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Lead asset SRK‑001/LY‑3200327 targets IL‑21 for the treatment of systemic lupus erythematosus. The company has completed and terminated at least one Phase 1 trial evaluating safety, tolerability, and pharmacokinetics in healthy participants. No published efficacy results are available as of May 2025.

Therapeutic areas: Immunology
Modalities: Biologics
Industry: Biotech

Drug pipeline

1 asset

LY3200327

Phase 2

Indications: Systemic lupus erythematosus

Partnerships

Eli Lilly and Company (original discovery/licensing partner for lead asset)

Beyond the preview

Go deeper on Sarkana Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sarkana Pharma, Inc..

Explore the full profile